Caris Life Sciences to Participate in the TD Cowen 46th Annual Health Care Conference

IRVING, Texas, Feb. 23, 2026 /PRNewswire/ — Caris Life Sciences^® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will participate in the TD Cowen 46^th Annual Health Care Conference, which will be held March 2-4, 2026, in Boston, Massachusetts.

About Caris Life Sciences
Caris Life Sciences^® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.

Caris Life Sciences Media:
Corporate Communications
[e-mail]
214.294.5606 

Investor Relations:
[e-mail]
917.689.3511

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-participate-in-the-td-cowen-46th-annual-health-care-conference-302694075.html

SOURCE Caris Life Sciences